Navigation Links
Pitt/Children's Hospital team: Cell membrane proteins could provide targets for broader vaccines
Date:12/22/2011

PITTSBURGH, Dec. 22 Vaccines with broader reach might be made by stimulating specialized immune cells to recognize foreign cell membrane proteins that are shared across bacterial species, say researchers from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine in a report published online today in Immunity. The approach could be particularly beneficial in preventing infection by multi-drug resistant organisms.

The genetic heritage of organisms such as oysters, frogs and fish indicate that a family of cell-signaling molecules called interleukin-17 (IL-17) arose in evolution before the advent of T cells, one of the main arms of the immune system in humans. The human IL-17 gene is turned on in a specialized group of immune cells in the T helper-cell lineage, known as Th17 cells, explained senior author Jay K. Kolls, M.D., professor of pediatrics and immunology, Pitt School of Medicine, and vice chair for translational research, Department of Pediatrics, and director, Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC.

"That development led us to think that perhaps Th17 cells confer some immunological advantage for eliminating infectious organisms beyond the antibody strategy that we typically employ when we make vaccines," he explained. "We wanted to better understand what role Th17 cells play."

The research team exposed mice to Klebsiella pneumoniae bacteria, a common cause of lung infection, and re-exposed them several weeks after they recovered from the first pneumonia. They found that the presence of the germ in both instances led to increased numbers of Th17 cells in the lungs and spleen. But when they blocked IL-17, they found the mice still developed immunity to infection. The antibody response, which is controlled by B cells, did not require IL-17 to become established.

Next, they infected mice bred to lack B cells, which make antibodies, with the bacteria. They found that the animals could become immunized against repeat infection as long as IL-17 was unblocked, allowing Th17 cells to develop an immunological memory of the Klebsiella bacteria.

The researchers determined also that while antibodies react to sugar complexes called polysaccharides in the bacterial coat or capsule, Th17 cells respond to protein complexes in the cell membrane. Those proteins, which are integral to the structure of the cell membrane, tend to be similar across bacterial strains, unlike the capsular polysaccharides, which are variable, Dr. Kolls said.

"Some current vaccines require generating a response to a number of these capsular sugars for effective immunization," he said. "An approach that harnesses the stability of the Th17 cell response to common proteins has the potential to simplify vaccination and provide a broader spectrum of coverage. This strategy may be particularly useful against bacteria that have diverse capsular sugars or multi-drug resistant organisms."


'/>"/>

Contact: Anita Srikameswaran
srikamav@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. The private sale of drugs in public hospitals
2. Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007
3. Bariatricfurnishings.com Launches Unique Eco-friendly Seating for Health Care, Hospitality, Assisted Living Centers, and Home Use at Competitive Prices
4. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
5. Most pandemic plans in Ontario hospitals have not been tested: Queens University study
6. American Heart Association Comment on Hospitalization of President Bill Clinton
7. Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment
8. SHARECOR Partners With Quantros, Inc. to Facilitate Core Measures and Regulatory Reporting in Louisiana Hospitals
9. Kaiser Foundation Health Plan and Hospitals Report Fourth Quarter and Fiscal Year 2009 Financial Results
10. Father Channels His Grief into Advocacy, Promotes Simple Actions to Make Hospitals Safer for Children
11. Catholic Health East and BayCare Health System Pledge $200,000 to Rebuild Hospital in Port-Au-Prince
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based insurance ... is spearheading a regional charity campaign organized to provide support to Christina Upchurch and ... this year, Christina and her children returned from out of town to find her ...
(Date:8/18/2017)... Raton, Fl (PRWEB) , ... August 18, 2017 ... ... largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy and ... associated with hormone imbalance and conditions of aging, such as menopause, andropause, thyroid ...
(Date:8/18/2017)... ... ... Alcovit, a lime-flavored beverage that rids the body of toxins linked to ... available through Jet.com. , After 25 years of development, the company released its ... quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with friends ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... and call tracking and monitoring solutions, announced today the launch of a redesigned ... a modern navigation and aesthetic, fully responsive design, and an enhanced search directory ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about saving the family ... is from Southwest Nebraska where she was raised on a farm. As Diane ... is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ have always been ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology: